Intensive care medicine

Cardiology

Pediatrics

Internal medicine

Heart disease

Medicine

Lung disease

Disease

Lung

New England Journal of Medicine

The efficacy and safety of nirsevimab in the treatment of medically attended respiratory syncytial virus (RSV) infections of the lower respiratory tract in otherwise healthy, late preterm and term infants were assessed in the phase 2B1 and phase 3 MELODY2 trials. An ongoing phase 2–3 trial (ClinicalTrials.gov number, NCT03959488. opens in new tab) is evaluating the safety and pharmacokinetics of nirsevimab in infants at risk for severe RSV infection of the lower respiratory tract who are eligible to receive palivizumab. [...]

Safety of Nirsevimab for RSV in Infants with Heart or Lung Disease or Prematurity